9/17/2020 · The Tempus xF assay is a non-invasive, liquid biopsy panel designed to provide clinical decision support for solid tumors.
The non-invasive Tempus|xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients. The assay is capable of detecting mutations in two variant classes in ~105 genes, including: Single Nucleotide Variants (SNVs) and insertions and deletions (indels), as well as Copy Number Amplifications, 9/14/2018 · Tempus Adds Tempus xF, a Liquid Biopsy Assay, to Sequencing Capabilities. NEWS. September 14, 2018. Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, has added a non-invasive genomic sequencing panel, Tempus xF, a liquid biopsy cell-free DNA assay that.
Any patients who receive Tempus testing may apply for Tempus’ Financial Assistance Program. If approved, the Program covers all Tempus|xF (liquid) or Tempus|xT (solid) testing within 18 months of Program approval. All U.S.-based patients may qualify. * Tempus testing is always conducted based on the medical judgement of an ordering physician.
2/8/2021 · Liquid biopsy (xF assay) is a minimally invasive tool that allows detection of MSI-H in PC patients, as well as longitudinal monitoring of response to treatment with pembrolizumab. Liquid biopsy conversion from positive to negative may provide reassurance that any residual lesions seen on imaging represent treated/inactive disease.
Tempus to Participate in the NCI- MATCH Clinical Trial, Genomic Profiling – Tempus, Oncology – Tempus, Genomic Profiling – Tempus, 4/7/2021 · Overview: Tempus’ xF liquid biopsy LDT assay allows for longitudinal monitoring of treatment response and resistance in patients with advanced prostate cancer.
9/17/2020 · The Tempus xT assay uses saliva and blood for germline DNA, and FFPE tissue (solid tumors and lymphoma), bone marrow/peripheral whole blood (heme) for tumor DNA and RNA. A patient can consent to or opt out of receiving genetic cancer predisposition results by completing the Patient Informed Consent form.
Fax the requisition form, financial assistance form, and accompanying documents to Tempus. Once the fax is received, we will request the tumor specimen from pathology. Retrieve a normal sample of blood or saliva from the patient, if required..
precision medicine. Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. With the world’s largest library of clinical and molecular data, and an operating system to make that data accessible and useful, we enable physicians to make real-time, data-driven decisions to deliver personalized …
8/2/2018 · Tempus xT is a genomic panel analyzing 595 genes that are relevant to the diagnosis, prognos is and therapeutic targeting of cancer. The panel sequences a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva specimen.
